Gene:
TLR4
toll-like receptor 4

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all variant annotations for TLR4

Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA
rs1927907 NC_000009.11:g.120472764C>T, NC_000009.12:g.117710486C>T, NG_011475.1:g.11305C>T, NM_003266.3:c.140+1757C>T, NM_138554.3:c.260+1757C>T, NM_138554.4:c.260+1757C>T, NM_138557.2:c.-340-1903C>T, XM_005252182.1:c.254+1757C>T
C > T
SNP
No VIP available CA VA
rs2770150 NC_000009.11:g.120463139A>G, NC_000009.12:g.117700861A>G, NG_011475.1:g.1680A>G, rs17420398, rs56438753, rs59057424
A > G
SNP
No VIP available CA VA
rs4986790 NC_000009.11:g.120475302A>G, NC_000009.12:g.117713024A>G, NG_011475.1:g.13843A>G, NM_003266.3:c.776A>G, NM_138554.3:c.896A>G, NM_138554.4:c.896A>G, NM_138557.2:c.296A>G, NP_003257.1:p.Asp259Gly, NP_612564.1:p.Asp299Gly, NP_612567.1:p.Asp99Gly, XM_005252182.1:c.890A>G, XP_005252239.1:p.Asp297Gly, rs52820966, rs59093760
A > G
SNP
D259G
No VIP available No Clinical Annotations available VA
rs4986791 NC_000009.11:g.120475602C>T, NC_000009.12:g.117713324C>T, NG_011475.1:g.14143C>T, NM_003266.3:c.1076C>T, NM_138554.3:c.1196C>T, NM_138554.4:c.1196C>T, NM_138557.2:c.596C>T, NP_003257.1:p.Thr359Ile, NP_612564.1:p.Thr399Ile, NP_612567.1:p.Thr199Ile, XM_005252182.1:c.1190C>T, XP_005252239.1:p.Thr397Ile, rs52826331
C > T
SNP
T359I
No VIP available CA VA
rs5030728 NC_000009.11:g.120474282G>A, NC_000009.12:g.117712004G>A, NG_011475.1:g.12823G>A, NM_003266.3:c.141-385G>A, NM_138554.3:c.261-385G>A, NM_138554.4:c.261-385G>A, NM_138557.2:c.-340-385G>A, XM_005252182.1:c.255-385G>A, rs57589733
G > A
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Alternate Names:  None
Alternate Symbols:  ARMD10; CD284; TLR-4; hToll
PharmGKB Accession Id: PA36552

Details

Cytogenetic Location: chr9 : q33.1 - q33.1
GP mRNA Boundary: chr9 : 120466453 - 120479769
GP Gene Boundary: chr9 : 120456453 - 120482769
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.
No related genes are available

Curated Information ?

Curated Information ?

Publications related to TLR4: 15

No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Associations between functional polymorphisms in the NFκB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease. The pharmacogenomics journal. 2014. Bank S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of TLR4 rs1927907 locus polymorphisms on tacrolimus pharmacokinetics in the early stage after liver transplantation. European journal of clinical pharmacology. 2014. Wang Zhaowen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine. Pharmacogenomics. 2013. Umićević Mirkov Maša, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Added value of pharmacogenetic testing in predicting statin response: results from the REGRESS trial. The pharmacogenomics journal. 2012. van der Baan F H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Gene polymorphism in toll-like receptor 4: effect on antibody production and persistence after acellular pertussis vaccination during adolescence. The Journal of infectious diseases. 2012. Gröndahl-Yli-Hannuksela Kirsi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nature medicine. 2010. Maroso Mattia, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. Pharmacogenomics. 2010. Kooloos Wouter M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. The New England journal of medicine. 2008. Bochud Pierre-Yves, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Statins inhibit toll-like receptor 4-mediated lipopolysaccharide signaling and cytokine expression. Pharmacogenetics and genomics. 2008. Hodgkinson Conrad P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Toll-like receptor 4 polymorphism associated with the response to whole-cell pertussis vaccination in children from the KOALA study. Clinical and vaccine immunology : CVI. 2007. Banus Sander, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Combining evidence of natural selection with association analysis increases power to detect malaria-resistance variants. American journal of human genetics. 2007. Ayodo George, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Variation in the toll-like receptor 4 gene and susceptibility to myocardial infarction. Pharmacogenetics and genomics. 2005. Holloway John W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes. American heart journal. 2004. Kolek Matthew J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation. 2003. Boekholdt S Matthijs, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Excess of rare amino acid polymorphisms in the Toll-like receptor 4 in humans. Genetics. 2001. Smirnova I, et al. PubMed

LinkOuts

NCBI Gene:
7099
OMIM:
114500
152430
603030
611488
UCSC Genome Browser:
NM_003266
RefSeq RNA:
NM_138554
NR_024168
NR_024169
RefSeq Protein:
NP_612564
RefSeq DNA:
NG_011475
NT_008470
UniProtKB:
D1CS53_HUMAN (D1CS53)
TLR4_HUMAN (O00206)
Ensembl:
ENSG00000136869
GenAtlas:
TLR4
GeneCard:
TLR4
MutDB:
TLR4
ALFRED:
LO039513V
HuGE:
TLR4
Comparative Toxicogenomics Database:
7099
ModBase:
Q9UK78
HumanCyc Gene:
HS06232
HGNC:
11850

Common Searches